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Abstract. Currently, endometriosis is an important public health issue due to the increasing number of cases and the risk 
of developing ovarian and endometrial tumours(10% of ovarian endometrial carcinomas are associated with uterine 
endometrioid carcinomas), which has led to increased research into the mechanisms of appearance and progression of this 
condition.Although endometriosis is considered a benign chronic disease, it can show an invasive character causing 
severe symptoms. Endometriosis has an increasing incidence, affecting 2% of the general population, being the third 
gynecological cause of infertility, chronic pelvic pain, dyspareunia and dysmenorrhea. Endometriosis affects 7-15% of 
women of childbearing age, with 25-30% of sterility cases having a significant social impact. Endometriomas are difficult 
to excise due to vascularization and increased adhesion of the cyst wall. Surgical treatment of endometriosis is effective 
in the short term. Surgery most often reduces ovarian reserve. The rate of recurrence after surgery can be reduced with the 
help of menstrual suppression medications such as hormonal contraceptives. Desogestrel treatment improves 




Until now, the etiology of endometriosis remains unknown, although several theories have been issued and have 
attempted to explain this inflammatory disease. Retrograde menstruation is the most accepted theory (Bulun, S.E., 2009; 
Aznaurova, Y.B., et al, 2014). 
Endometriosis is a relatively frequent gynecological disease, usually characterized by infertility or chronic pelvic pain. In 
the ovary, most commonly, endometriosis is manifested by the appearance of endometriomas, those cysts containing a 
chocolate-like sustance and a pseudocapsula that is adjacent to normal ovarian tissue, adherent to peritoneum, fallopian 
tubes and intestine (Giudice, L.C., 2010; Verkauf, B.S., 1987). 
This disease can be confirmed only following surgery, usually laparoscopic. Endometriomas are in particular difficult to 
remove because the surgery can reduce the ovarian reserve, the capsule being very adherent and well vascularized. 
Surgical resection of endometriotic implants is often associated with partial disappearance of symptoms or their relapse, 
therefore prolonged medical treatment may be necessary (Lucidi, R.S., et al, 2005; Vercellini, P, et al, 2011). 
Surgical treatment of endometriosis is effective in the short term, but if the patient does not get pregnant shortly after 
surgery, the recurrence is common.  The rate of recurrence after surgery may decrease with the use of menstrual 
suppression treatment consisting of the administration of hormonal contraceptives. Desogestrel is a progestogen derived 
from 19-nortestosterone, widely used for oral contraception, both in combination with ethinylestradiol and plain, in mini-
pill contraceptives (Peltecu, Gh., 2014). 
Endometriosis appears to be a complex disorder in which a variety of factors (environmental, hormonal, immune and 
genetic) are ivolved, being considered in a hormone-addictive disorder (Bedaiwy, M.A. & Falcone, T., 2004). 
Many studies have proved that desogestrel has superior properties than other progestative pills in the preoperative 
treatment of endometriotic lesions and that is why we studied its effects when treatment was continued postoperatively by 
the patients who had undergone surgery for removing their endometriotic cysts (Wu, M.Y. &Chauk, H; 1996; Foda, A.A, 
et al, 2012). 
The quality of life correlated with health is a multidimensional concept that involves physical, psychological and social 
aspects associated with the disease and its treatment(Bedaiwy, M.A., et al, 2002). 
The purpose of the study.This study sought to evaluate the effects of continuous treatment with desogestrel versus oral 
contraceptives combined (0.02 mg ethinylestradiol/3 mg drospirenone) in the prevention of postoperative recurrence of 
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MATERIAL AND METHOD 
 
Our study included 300 patients with endometriotic ovarian cysts that undergone surgery at “Elena Doamna” Clinical 
Hospital of Obstetrics and Gynecology in Iaşi, in the period of time 2010 – 2017. The cysts were diagnosed during pelvic 
examination or transvaginal ultrasound performed for infertility, chronic pelvic pain, abnormal vaginal bleeding or during 
a routine control (fig. 1). The minimum diameter of a cyst was 20 mm, and patients with septal cysts, papillomas or 




Fig. 1. Ultrasound changes preoperatively 
(personal collection) 
 
We also excluded from the study women with a body mass index > 30, with neoplasms, autoimmune diseases, diabetes 
mellitus, infectious diseases, developing pregnancy or under anti-inflammatory or hormonal treatment. Every patient 
enrolled in the study signed the consent form. 
The patients were divided into 3 batches, 100 of the patients followed treatment with desogestrel (Cerazette) 75 mg, 100 
of the patients were treated with combined oral contraceptives (0,02 mg ethinylestradiol/3mg drospirenone), and 100 
patients did not follow any treatment, as they refused treatment because they wanted to undergo surgery and conceive 
immediately after it. The duration of treatment was 6 months before laparoscopy and another 3-6 months after surgery. 
During the surgery, we evaluated the cyst size, vascularization, uterine and contralateral ovary position, presence of 
adhesions, and ease of dissection of cyst coat from normal ovarian tissue. All cases were confirmed by a pathological 
examination that highlighted histological aspects of endometriosis: endometrial stroma, endometrial epithelium, glands 
responsive to hormone stimuli and hemosiderin deposits.  
Intraoperatively there was less bleeding when removing the cyst coating, which suggests a better cleavage plane between 
the cyst coating and the normal ovarian tissue. 
Desogestrel treatment was well tolerated and no patient gave up the study due to adverse effects (tab. I). 
 
Table I. Tolerance of Desogestrel treatment 
  
Desogestrel COC 
Cleavage plane +++ +/- 
Bleeding +/- +++ 
Adhesions + +++ 
Duration of intervention + ++ 
 
Patients were monitored by Doppler endovaginal ultrasound every three months. The Characteristics of the two treatment 
groups were compared using Student’s t- and  2-tests. 
The patients were aged between 18 and 45 (the mean age being of 34 years old), all still having menstruation. 206 of the 
patients had infertility associated with endometriosis. 
 
RESULTS AND DISCUSSIONS 
 
The mean age was significantly higher in the group of patients receiving COC (28.98 vs 39.24 y; 
p=0.05). 
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Preoperative, it was found by ultrasonograph that in over 80% of the patients treated with 




Fig. 2. Preoperative ultrasound changes 
 
For the group treated with desogestrel, 80% of patients had amenorrhea, 58% had irregular 
bleeding and 17% of the women accused regular bleeding. Patients described these bleeds as 
being much less quantitatively than normal menstruation. 51% of the patients accused a weight 
gain of a maximum 5 kg, 28% of the women reported vaginal dryness and sexual discomfort, and 
55% of the patients reported a decrease in libido (fig. 3). 
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Patients treated with combined oral contraceptives did not have the adverse effects of desogestrel 
except for weight gain in a similar proportion, but instead 80% of the patients accused breast-
stress, 10% headache, 7% nausea; symptomatology has improved from one month to the next.  
Therefore, both batches tolerated treatment well and no patient gave up the study due to adverse 
effects. 
In the group with desogestrel, 70% of the patients were pregnant in the first year after 
laparoscopy, in the group who received oral contraceptives 67% were pregnant and in the non-
treated group 63% of the patients conceived in the first year postoperatively. The cyst recurrence 
rate was significantly lower (6%) in the group of patients receiving desogestrel, respectively 7% 




Fig. 4. Patient monitoring in the first postoperative year 
 
According to the American Society for Reproductive Medicine, "Endometriosis should be 
considered a chronic illness that requires a life-long management plan to maximize the use of 
medication and avoid repeated surgical procedures" (Johnson, N.P. &Hummelshoj, L., 2013). 
Hormonal drugs are given to try to stop ovulation for as long as possible in order to keep 
the implants or lesions from being aggravated. These can include oral contraceptives, 
progesterone drugs, and GnRH agonists (Barbieri, R.L., et al, 1986; Pittaway, D.E. & Douglas, 
L.W., 1989; Koyama, N, et al, 1993). Most of these therapies can only be given for a limited 
amount of time, and the side effects can cause problems for some women. Hormonal drug 
therapy is used to ward off symptoms and is often most effective when used after surgical 
treatment has been done (May, K.E., et al, 2010). 
Endometriosis can cause infertility in many women, but with proactive treatment, the 






















Drug treatment should contribute to two main objectives: reducing pain for prolonged periods 
and preventing the aggravation of the disease between the conservative surgery and the moment 
of conception. 
Progesterone treatment optimizes intraoperative conditions and reduces the risk of recurrence of 
endometriosis. 
Continuous treatment with desogestrel prevents recurrence of endometrial cysts and clinical 
symptoms related to endometriosis. Desogestrel offers the associated benefits of a well-tolerated 
contraceptive and allows for a safe postponement of the planning of a child without the risk of a 
relapse of the disease.  
The treatment has a low cost, is effective and brings a considerable improvement in the quality of 
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